OMER
Omeros Corporation · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website omeros.com
- Employees(FY) 196
- ISIN US6821431029
Performance
-3.09%
1W
+0.58%
1M
-29.45%
3M
+128.48%
6M
+5.5%
YTD
-41.92%
1Y
Profile
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Technical Analysis of OMER 2024-05-10
Overview:
In analyzing the technical indicators for OMER over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...
Recent News & Updates
- 2024-05-16 01:10
Q1 2024 Omeros Corp Earnings Call(Yahoo Finance)
- 2024-05-15 15:10
- 2024-05-15 08:55
OMER Stock Earnings: Omeros Misses EPS for Q1 2024(Investorplace)
- 2024-05-15 04:11
Omeros: Q1 Earnings Snapshot(Yahoo Finance)
- 2024-05-15 04:02
- 2024-05-09 20:50
- 2024-05-08 20:50
- 2024-04-02 00:41
Q4 2023 Omeros Corp Earnings Call(Yahoo Finance)
- 2024-04-01 23:22
- 2024-04-01 09:53
OMER Stock Earnings: Omeros Misses EPS for Q4 2023(Investorplace)
- 2024-04-01 05:32
- 2024-04-01 04:17
Omeros: Q4 Earnings Snapshot(Yahoo Finance)
- 2024-04-01 04:02
- 2024-03-26 20:30
- 2024-03-16 22:02
Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade(Yahoo Finance)
- 2024-02-19 20:00
- 2024-02-06 20:34
3 Sleeper Stocks Under $15 Ready to Explode by 2029(Yahoo Finance)
- 2024-01-31 20:11
- 2023-12-24 00:08
7 Short-Squeeze Stocks That Are Screaming for Speculation(Yahoo Finance)
- 2023-11-11 02:01
- 2023-11-09 20:43
Q3 2023 Omeros Corp Earnings Call(Yahoo Finance)
- 2023-11-09 03:33
Omeros: Q3 Earnings Snapshot(Yahoo Finance)
- 2023-11-09 03:02
- 2023-11-05 19:00
- 2023-11-02 21:05
- 2023-11-01 21:05
- 2023-10-18 20:30
- 2023-10-15 20:36
- 2023-10-15 19:59
- 2023-10-15 19:44
Page 1 of 4
previousnext